Patent · US Active

Modified vaccinia virus ankara for the vaccination of neonates

US7897156B2 · kind B2 · utility

11Cited by

24References

12Claims

0Family size

Assignee

Bavarian Nordic A/S · DK

Inventors

Mathias Ackermann · Bassersdorf, CH
Mark Suter · Luzern, CH
Hans Peter Hefti · Zürich, CH
Marco Franchini · Suhr, CH
Sabine Vollstedt · Zürich, CH
Paul Chaplin · Munich, DE

Key dates

Filing date	May 12, 2008
Grant date	Mar 1, 2011
Priority date	—
Expiry date	Oct 17, 2028

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention concerns the use of a virus to increase the number of dendritic cells or their precursor cells in an immunocompromised animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara which is capable of infecting the cells of a neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.